Skip to main content

Table 2 Length of treatment (LOT) per indication

From: Detecting inappropriate total duration of antimicrobial therapy using semi-automated surveillance

Definitive diagnosis

Total (n)

Treatment courses with post-discharge treatment (n;%)

Percentage of total treatment duration given post-discharge (%;SD)*

LOT in days,

(median; IQR)

Recommended course duration**

Guideline adherence***

(%)

Treatment courses too long (%)

UTI—Cystitis

420

231 (55)

63 (21)

6.5 (4.0–10.0)

3–7 days

53

31

UTI—Complicated UTI

241

164 (68)

63 (18)

12.0 (7.0–15.0)

7–14 days

60

15

UTI—CAD

28

15 (54)

65 (18)

11.0 (4.8–14.0)

7–14 days

57

14

UTI—Kidney transplant

47

28 (60)

59 (17)

11.0 (5.5–15.0)

   

UTI—Other (not specified)

89

60 (67)

68 (18)

13.0 (7.0–15.0

   

RTI—CAP-m

328

142 (43)

54 (20)

6.0 (5.0–8.0)

5 days

35

40

RTI—CAP-s

90

17 (19)

46 (24)

5.0 (3.0–7.0)

5 days

29

31

RTI—HAP

41

6 (15)

37 (24)

6.0 (4.0–8.0)

5–7 days

46

24

RTI—Aspiration

82

23 (28)

51 (20)

6.5 (5.0–9.0)

5 days

26

50

RTI—COPD

73

32 (44)

58 (18)

6.0 (3.0–8.0)

7 days

38

14

RTI—Abscess/empyema

23

9 (39)

55 (19)

8.0 (5.5–15.0)

   

RTI—Other (not specified)

154

51 (33)

56 (17)

6.0 (3.0–8.8)

   

CNS infection

51

7 (14)

70 (21)

8.0 (3.0–11.5)

   

CVL infection

29

11 (38)

59 (17)

7.0 (4.0–13.0)

   

ENT infection

106

88 (83)

63 (14)

10.0 (9.0–13.0)

7–14 days

75

10

Gastro-enteritis

40

14 (35)

60 (21)

5.0 (3.0–8.0)

   

Gynaecological infection

165

91 (55)

68 (16)

7.0 (2.0–11.0)

   

Intra-abdominal infection

464

145 (31)

52 (19)

6.0 (4.0–8.0)

   

Sepsis e.c.i./unkown

270

53 (20)

56 (20)

4.0 (3.0–7.0)

   

Skin or soft tissue infection

336

214 (64)

62 (19)

11.0 (7.0–15.0)

10–14 days

44

16

Other (not specified)

157

49 (31)

63 (19)

6.0 (3.0–10.0)

   

Total

3390

1502 (44)

60 (19)

7.0 (4.0–11.0)

   

Excluded****

232

      
  1. *Proportions are only given for treatment courses with post-discharge treatment
  2. **Recommended by Dutch guidelines (www.swabid.nl)
  3. *** One additional day was allowed as each calendar day on which a dose was given was counted as a full day of treatment
  4. **** Indications that were rarely selected, i.e. in less than 20 treatment courses, or that would require > 21 days of treatment according to our national guidelines were excluded. These included the following indications: Bone and Joint infection, S. aureus bacteraemia, Endovascular infection, Eye infection, Febrile neutropenia, Fungal infection, Mediastinitis, UTI–cyst infection and chronic prostatatitis
  5. SD Standard deviation, UTI Urinary tract infection, UTI-CAD Catheter-associated urinary tract infection, RTI Respiratory tract infection, CAP-m Community-acquired pneumonia mild-to-moderate severe, CAP-s Community-acquired pneumonia severe, HAP Hospital-acquired pneumonia, COPD Chronic obstructive pulmonary disease, CNS Central nervous system, CVL Central venous line